Somatic mutations in KEAP1, NFE2L2, or other Nrf2 pathway components were not reported in this study, which is not surprising, knowing that the frequency of such mutations in thyroid cancer is lower than in other cancer types with activated Nrf2 signaling [64,65], and given the small sample size of the specific study [66]. This evidence concerns the gene NFE2L2 and cancer.